JCG
RVNC

JHL Capital Group’s Revance Therapeutics, Inc. RVNC Stock Holding History

JHL Capital Group’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-110,000
Closed -$1.92M – 20
2016
Q1 		$1.92M Buy
+110,000
New +$2.24M 0.18% 15

Other funds holding RVNC

EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
NHG
NQ HCIF GP Raleigh, North Carolina $50.2M AUM 45.53% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JHL Capital Group's RVNC Position: Q2 2016 in Review

JHL Capital Group sold out of Revance Therapeutics, Inc. (RVNC) in Q2 2016, closing a stake of 110,000 shares — an estimated $1.92M sold.

JHL Capital Group first reported a position in RVNC in Q1 2016 and held it in 1 quarter. The position peaked at $1.92M in Q1 2016. 82 funds tracked by Wall St. Rank hold RVNC as of Q2 2016.

  • JHL Capital Group reported no remaining Revance Therapeutics, Inc. position as of Q2 2016 after selling out during the quarter.
  • JHL Capital Group sold 110,000 Revance Therapeutics, Inc. shares in Q2 2016, an estimated $1.92M.
  • JHL Capital Group first reported a position in Revance Therapeutics, Inc. in Q1 2016 and held it in 1 quarter.
  • JHL Capital Group's Revance Therapeutics, Inc. position peaked at $1.92M in Q1 2016.
  • 82 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q2 2016.

Based on JHL Capital Group's 13F filing for Q2 2016, filed 15 Aug 2016.